TP-0903

PreclinicalSmall molecule

TP-0903 is one of 22 small molecule programs targeting Refractory Acute Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Acute Myeloid LeukemiaRecruiting

Refractory Acute Myeloid LeukemiaPreclinical

Recruiting

Competition

Competitive Landscape

21 competitors in Refractory Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 1

2 2

Cytosar

Teva

Phase 1

2 3

Trexall

Jazz Pharmaceuticals

Phase 1

1 4

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 1

2 5

Revuforj

SSyndax Pharmaceuticals

Phase 1

2 6

Dacogen

Sun Pharmaceutical Industries, Inc.

Preclinical

1 7

Peony

Takeda

Preclinical

1 8

Xospata

Astellas

Preclinical

1 9

Cerubidine

HHikma Pharmaceuticals LLC

Preclinical

1 10

Intrathecal Chemotherapy

PPrincess Maxima Center for Pediatric Oncology

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2032

PreclinicalRecruiting

Refractory Acute Myeloid Leukemia

NCT03013998

Clinical

Trials by Indication[1]

Phase 11 trial

Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL

Terminated· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT03572634·3 enrolled

Patients With Advanced Solid Tumors1 trial

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02729298·177 enrolled

Refractory Acute Myeloid Leukemia1 trial

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Recruiting·BBeat AML, LLC·Preclinical·NCT03013998·3,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for TP-0903. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TP-0903 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TP-0903. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma America, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sumitomo Pharma America, Inc.

TP-0903

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2032

Trials by Indication[1]

Phase 11 trial

Patients With Advanced Solid Tumors1 trial

Refractory Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News